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Correspondence: Livio Trentin (e-mail: livio.trentin@unipd.it), RobertoMarasca (e-mail: roberto.marasca@unimore.it).nfections represent the most common and potentially life- develops a flu-like syndrome, while almost 1% experiencesWNVI threatening complication in patients with haematologicalmalignancies, particularly in subjects with a lymphoidneoplasm.1 The increased risk of infections is ascribed to
inherent disease-related immunological impairment, and can be
worsened by chemo-immunotherapy and targeted agents.2–4
While bacterial and mycotic infections5,6 are known to be
recurrent in haematological patients, viral infections were often
overlooked but recently they became a world-wide concern.
West Nile virus (WNV) is an arthropod-borne virus commonly
transmitted to humans mainly by Culex mosquitoes, although
transmission through blood transfusion or organ transplantation
has been reported.7 WNV is maintained in a continuous cycle
within mosquitos and birds, wherein mosquitos are the vectors
and the birds are the reservoir. Humans, just like horses and other
mammalians, act as dead-end hosts and do not contribute to the
spreading of the infection. In most immunocompetent patients
WNV infection is usually asymptomatic, 20% of infected people
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neuroinvasive disease (WNVND).7 Symptoms, when occurring,
generally develop after an incubation period typically lasting 2 to
6 days, but may extend to 14 days, or even longer in
immunocompromised subjects. WNVND can occur as meningi-
tis, encephalitis, or acute flaccid paralysis.8
So far, the knowledge on the clinical course, the rate of
central nervous system (CNS) involvement and the outcome of
WNV infection in patients with haematological malignancies is
scanty, being limited to only a few reports.9 The aim of this
multicentre studywas toanalyse the clinical features and theoutcome
of WNV infection in patients with malignancies of B-cell lineage.
For this purpose, we retrospectively collected clinical data from
21 patients diagnosed with a B-cell lymphoid neoplasm who
experienced WNV infection during the last 7 years at 8 Italian
institution. Thirteen patients had chronic lymphocytic leukaemia
(CLL), 5 non-Hodgkin lymphomas (3 follicular lymphomas, 1
high-grade lymphoma, and 1 extranodal marginal zone lympho-
ma), 1 hairy cell leukaemia, 1 Hodgkin lymphoma, and 1 B-cell
precursor acute lymphoblastic leukaemia. Anti-WNV antibody
and WNV-ribonucleic acid (RNA) were assessed in blood and
cerebrospinal fluid (CSF) in all patients. CNS imaging studies
(ie brain computer tomography scan and/or magnetic resonance
immaging) were performed in all the patients with WNVND, in
order to rule out other causes of neurological involvement such as
bleeding or lymphoma/leukaemia localization. CNS symptoms
associated with the presence of WNV-RNA and/or WNV-IgM
in the CSF were applied as diagnostic criteria for WNVND,
according to the current guidelines.8
The primary endpoint of the study was to evaluate the rate of
WNVND. The secondary endpoints included the median overall
survival (OS), calculated as time from WNV infection to death
(event) or last known follow-up (censored), and WNV-related
survival. Mann-Whitney and Fisher exact tests were used to
compare continuous and categorical variables. This multicentre
retrospective study was approved by the local research ethics
committee of PaduaHospital and carriedout according toHelsinki
declaration. Informed consentwas obtained fromall alive patients.
Authors can share patients’ data upon reasonable request.
Clinical and laboratory features of the 21patients are reported in
Table 1 and in Figure 1A. Sixteen (76%) participants had received
one previous anti-leukaemia/lymphoma treatment (0–3) and 10
(57%) had an active haematological disease at the time of WNV
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relapsed diseases. The median time from lymphoid neoplasm
diagnosis to WNV infection was 6.5±4.5 years, being longer in
patients withWNVND (3.5±2.9 vs 7.4±4.4 in cases without and
with WNVND, P=0.0358). Patients who developed WNVND
were more likely relapsed cases and had significantly lower serum
immunoglobulin levels (IgG, IgA, and IgM; Figure 1B) as
compared to subjects without neurological involvement (Table 1).
All the patients presented fever (max value range 38.2–40°C),
while 17 (81%) reported fatigue, 9 (42%) arthralgia, and 4 (19%)
dyspnoea.As shown inTable 1, anti-WNV IgMwasdetected in the
blood of 14 patients (67%), with a clear difference between
patients with or without WNVND (53% vs 100%), suggesting
that impaired humoral immunity may favour viral diffusion to
CNS. Consistently, anti-WNV IgM were negative in CSF of half
of WNVND cases. The presence of WNV-RNA in urine was
identified in 4 of 11 assessed patients. Twenty (95%) subjects
developed neurological symptoms, such as confusion, amnesia, or
headache, but only 15/21 (71%, Figure 1A) fulfilled the criteria for
WNVND.All the six patientswithoutWNVNDand6of 15 (40%)
with WNVND showed complete resolution of the infection
without any sequalae. The remaining 9 of 15 with WNVND
manifested gait instability, depression, or amnesia at 1 year from
infection occurrence. Given the lack of a standard therapeutic
approach, our patients received different treatments, including
polyclonal intravenous immunoglobulins (57%), corticosteroids
(33%), antiviral drugs (29%: 24% acyclovir and 5% ganciclovir),
and levetiracetam (29%: 15% as prophylaxis and 14% for seizure
treatment).Most casesweremanaged in an inpatient setting, due to
high-grade fever and neurological symptoms or clinical manifes-Table 1
Clinical and Microbiological Characteristics of the Patients.
Variables All Patients WN
Number of cases 21











WBC (n/ml) 17,668±2468 33,3
ANC (n/ml) 5051±3133 48
Hb (g/L) 125±25
PLT (n/ml) 154,650±62,203 175,4
eGFR (ml/min) 77±21
IgG (g/L) 6.6±2.7 9
IgA (g/L) 1.0±0.9 2







ANC = absolute neutrophil count, B-ALL = B-cell acute lymphoblastic leukemia, CLL = chronic lymphocytic
HCL = hairy cell leukemia, HL = Hodgkin lymphoma, NHL = non-Hodgkin lymphomas, PLT = platelets
a 3 cases of follicular lymphoma, 1 extranodal marginal-zone lymphoma, and 1 high-grade B cell lymph
2
tations such as tremor and dizziness seizures and coma, requiring
intravenous fluids or respiratory support.
Among the CLL subgroup, accounting for 62% of all cases, 8
of 13 patients had a relapsed disease and 4 harboured high-risk
cytogenetics (ie 17p abnormalities or 11q deletion) (Table 1).
WNVND was diagnosed in 9 (69%) CLL patients, 3 of whom
were receiving a kinase inhibitor (2 ibrutinib and 1 idelalisib-
rituximab) at the time of the infection onset. Both patients taking
ibrutinib as first-line therapymounted protective anti-WNV IgM,
contributing to WNV clearance and complete recovery, without
any permanent neurological sequelae. Conversely, the heavily
pre-treated patient receiving idelalisib-rituximab showed persis-
tent WNR-RNA load in blood and CSF, resulting in progressive
neurological impairment. In the latter case, it is conceivable that
rituximab and previous therapies, rather than idelalisib, blunted
humoral immunity, compromising the host response.
After amedian follow-up of 12.4months, 8 patients (37%) died
[6 cases of WNVND and 2 non-WNV-related deaths (1 Richter
syndrome and 1 stroke)]. Among the patients with WNVND, the
mortality rate was 40%. The 12-month OS of the whole cohort
was 68% and the median OS was 14.4 months (Figure 1C). The
median WNV-related survival was 8 months for patients with
WNVND, while no death due to WNV infection was reported in
subjects without neuro-invasive disease (P=0.0463, Figure 1D).
Since 2008, the incidence of WNV infection increased
substantially in South Europe, with peaks of cases registered in
2013 and 2015,10 likely due to environmental changes that
favour mosquitos breeding and propagation. While most of the
infected patients are asymptomatic, some of them can experience



























leukaemia, CSF = cerebrospinal fluid, eGFR = estimated glomerular filtration rate, Hb = hemoglobin,
count, RNA = ribonucleic acid, WBC = white blood cell count, WNV = West Nile virus.
oma.
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Figure 1. Descriptive graphs and survival curves. (A) The upper left panel shows the apple-pie graph of WNV infection; 71% of patients had a WNVND, while
29%did not have a documented spread to central nervous system. (B) The upper right panel reports a scatter plot of serum IgG, IgA, and IgM immunoglobulin levels
in patients with (n=15) and without WNVND (n=6). Immunoglobulins were measured once for each patient within 30 days before WNV infection. Cases with
WNVND had significantly lower immunoglobulin levels as assessed by Mann-Whiteney U test. the lower panels report the overall survival of the whole cohort (C) and
the WNV-related survival in patients with and without WNVND (D). Patients with WNVND have a short WNV-related survival (P=0.0463). WNV = West Nile virus,
WNVND = West Nile virus neuroinvasive disease.
(2020) 4:3 www.hemaspherejournal.comimmunity have been supposed to be the most relevant risk factors
for CNS involvement.11 These conditions commonly coexist in
subjects with lymphoid cancers, arousing concerns on WNV
outbreaks in this population. Furthermore, the lack of approved
vaccine or specific antiviral drugs narrow the therapeutic
possibilities for the management of the disease, these latter being
mainly based on supportive care. Overall, only 17 cases of
WNVND in the context of a haematological neoplasm have so
far been reported in the literature, mostly published as case
reports.9 Interestingly, a paper reported 1 CLL patient developing
WNVND while receiving ibrutinib.9
To our knowledge, this is the largest study that described
clinical and laboratory features ofWNV infection in patients with
B-cell malignant lymphoid disorders, evaluating, for the first
time, the rate of WNVND and the survival outcomes in this
setting.3
In our series, WNVND appeared to be very common, involving
71% of cases and causing 6 of 8 deaths. The risk of WNVND is
estimated to be 0.6–0.7% in the immunocompetent individuals
and 40% among solid transplant-recipients.12 Notably, in our
study WNVND was associated with a dismal outcome: only 1 of
4 patients survived longer than 12 months after infection onset
(with a median OS of 8 months) and mortality was as high as
40%, approximately four-fold higher as compared to unselected
populations.7,11 Not surprisingly, hypogammaglobulinemia and
the presence of a relapsed disease emerged as risk factors for CNS
involvement.
The present study provides clinically relevant information on a
potentially life-threatening viral disease that significantly worsens
the outcome in patients with lymphoid neoplasms, accounting for
high mortality and morbidity. It should be noted that, as mildly
symptomatic patients are unlikely investigated for possible WNV
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estimated. Moreover, the diagnostic process may be tricky in
rituximab-treated patients, whose serologic tests are often
negative.13 Therefore, haematologists are urged to start a timely
and proper diagnostic workup, consisting of both serologic and
molecular tests, in patients with unexplained fever and/or with
mild neurological symptoms, especially those receiving chemo-
immunotherapy or targeted therapy in endemic areas and during
summer period. Currently, the implementation of dedicated
policies for the prevention, surveillance, and control of WNV
infection represents the most effective measure against virus
outbreaks. Thus, future efforts should be directed to empower
national surveillance systems and accomplish specific screening
and treatment recommendations for haematological patients.
Moreover, the protective effect of immunoglobulin replacement
therapy remains to be elucidated.
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